Sutro Biopharma Operating Income Over Time
| STRO Stock | USD 15.73 0.09 0.58% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Sutro Biopharma Performance and Sutro Biopharma Correlation. Will Biotechnology sector continue expanding? Could Sutro diversify its offerings? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sutro Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.60) | Revenue Per Share | Quarterly Revenue Growth 0.138 | Return On Assets | Return On Equity |
Understanding Sutro Biopharma requires distinguishing between market price and book value, where the latter reflects Sutro's accounting equity. The concept of intrinsic value - what Sutro Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Sutro Biopharma's price substantially above or below its fundamental value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Sutro Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Sutro Biopharma and related stocks such as Artiva Biotherapeutics, Adverum Biotechnologies, and Precision BioSciences Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARTV | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (53.3 M) | (59.8 M) | (30.7 M) | (67.3 M) | (60.6 M) | (63.6 M) |
| DTIL | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (22 M) | (47.9 M) | (87.2 M) | (109.8 M) | (39.4 M) | (62.3 M) | (43.7 M) | (26.2 M) | (23.5 M) | (24.7 M) |
| PLRX | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (30.9 M) | (1.2 M) | (41.6 M) | (20 M) | (127.2 M) | (184.1 M) | (228.4 M) | (205.5 M) | (195.3 M) |
| GUTS | (29.9 M) | (29.9 M) | (29.9 M) | (29.9 M) | (29.9 M) | (29.9 M) | (29.9 M) | (29.9 M) | (29.9 M) | (29 M) | (36.9 M) | (49.4 M) | (50.8 M) | (93.5 M) | (93.5 M) | (84.2 M) | (80 M) |
| IFRX | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (6.9 M) | (19.4 M) | (37.5 M) | (63.9 M) | (38.9 M) | (56.4 M) | (55.1 M) | (44.9 M) | (53 M) | (47.7 M) | (50.1 M) |
| MGX | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (44.6 M) | (78.5 M) | (88.9 M) | (88.9 M) | (80 M) | (84 M) |
| CNTB | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (30.3 M) | (99.2 M) | (117.7 M) | (62.1 M) | (22.5 M) | (20.2 M) | (21.2 M) |
| STTK | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (25.1 M) | (36.9 M) | (45.3 M) | (103.3 M) | (92 M) | (80.6 M) | (72.5 M) | (76.1 M) |
| KLRS | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (26.7 M) | (71.3 M) | (169.8 M) | (14 M) | (13.5 M) | (55.3 M) | (49.7 M) | (52.2 M) |
Sutro Biopharma and related stocks such as Artiva Biotherapeutics, Adverum Biotechnologies, and Precision BioSciences Operating Income description
Operating Income is the amount of profit realized from Sutro Biopharma operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Sutro Biopharma is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Sutro Biopharma | STRO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 111 Oyster Point |
| Exchange | NASDAQ Exchange |
USD 15.73
Check out Sutro Biopharma Performance and Sutro Biopharma Correlation. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Sutro Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.